3/19
04:36 pm
inbx
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results [Yahoo! Finance]
3/19
04:10 pm
inbx
Inhibrx Biosciences GAAP EPS of -$2.11 misses by $0.03 [Seeking Alpha]
Medium
Report
Inhibrx Biosciences GAAP EPS of -$2.11 misses by $0.03 [Seeking Alpha]
3/19
04:00 pm
inbx
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Medium
Report
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
3/2
04:13 pm
inbx
Inhibrx Announces Participation in Upcoming Scientific Conference [Yahoo! Finance]
Medium
Report
Inhibrx Announces Participation in Upcoming Scientific Conference [Yahoo! Finance]
3/2
04:00 pm
inbx
Inhibrx Announces Participation in Upcoming Scientific Conference
Medium
Report
Inhibrx Announces Participation in Upcoming Scientific Conference
2/26
05:47 pm
inbx
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight [Yahoo! Finance]
Medium
Report
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight [Yahoo! Finance]
1/24
05:08 am
inbx
Inhibrx Biosciences (NASDAQ:INBX) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Inhibrx Biosciences (NASDAQ:INBX) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
1/13
03:17 pm
inbx
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too [Seeking Alpha]
Low
Report
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too [Seeking Alpha]
12/28
10:27 am
inbx
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts [Yahoo! Finance]
Low
Report
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts [Yahoo! Finance]